$66.47
7.07%
Nasdaq, May 09, 09:46 pm CET
ISIN
US00182C1036
Symbol
ANIP

ANI Pharmaceuticals, Inc. Stock price

$66.30
+0.29 0.44% 1M
+4.56 7.39% 6M
+11.02 19.93% YTD
+0.42 0.64% 1Y
+40.18 153.83% 3Y
+31.50 90.52% 5Y
+14.05 26.89% 10Y
Nasdaq, Closing price Fri, May 09 2025
-5.23 7.31%
ISIN
US00182C1036
Symbol
ANIP
Sector
Industry

Key metrics

Market capitalization $1.43b
Enterprise Value $1.92b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 28.88
EV/Sales (TTM) EV/Sales 2.85
P/S ratio (TTM) P/S ratio 2.12
P/B ratio (TTM) P/B ratio 3.47
Revenue growth (TTM) Revenue growth 30.26%
Revenue (TTM) Revenue $674.07m
EBIT (operating result TTM) EBIT $1.27m
Free Cash Flow (TTM) Free Cash Flow $66.61m
Cash position $155.22m
EPS (TTM) EPS $-1.27
P/E forward 57.28
P/S forward 1.84
EV/Sales forward 2.47
Short interest 13.74%
Show more

Is ANI Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

ANI Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

Buy
88%
Hold
13%

Financial data from ANI Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
674 674
30% 30%
100%
- Direct Costs 350 350
38% 38%
52%
324 324
22% 22%
48%
- Selling and Administrative Expenses 202 202
80% 80%
30%
- Research and Development Expense 45 45
15% 15%
7%
77 77
32% 32%
11%
- Depreciation and Amortization 76 76
25% 25%
11%
EBIT (Operating Income) EBIT 1.27 1.27
98% 98%
0%
Net Profit -23 -23
167% 167%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about ANI Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ANI Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
3 days ago
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Vamil Divan - Guggenheim Securit...
Neutral
GlobeNewsWire
3 days ago
BAUDETTE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2025.
Positive
Seeking Alpha
6 days ago
ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new formulations of established drugs, minimizing launch expenses and maximizing market potential. INZIRQO and TEZRULY could generate significant revenue, with potential annual revenues of $1 billion an...
More ANI Pharmaceuticals, Inc. News

Company Profile

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Head office United States
CEO Nikhil Lalwani
Employees 897
Founded 1996
Website www.anipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today